Lifeward Ltd. LFWD
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -57.37%
- 1 year
- -55.24%
- Market cap
- 8.37M
- Revenue (ttm)
- 23.28M
- Profit margin
- -102.03%
- EPS (ttm)
- -14.50
- Shares out
- 8.81M
- Forward P/E
- -1.59
- YTD return
- -57.37%
- 1-year return
- -55.24%
- Volume
- 21.81K
- Avg volume
- 11.74K
- Open
- 3.25
- Previous close
- 3.20
- Day's range
- 2.84 – 3.26
- 52-week range
- 2.84 – 9.61
- Beta
- 2.08
- Price target
- 9.50 (+222.0%)
Key statistics
- 50-day average
- 2.11
- 200-day average
- 3.67
- Enterprise value
- 7.13M
- Price / sales
- 0.56
- Price / book
- 0.28
- Revenue growth
- 401.60%
- Free cash flow
- -13.66M
- Total cash
- 15.13M
- Total debt
- 1.29M
- Return on equity
- -49.66%
- Short % of float
- 1.88%
Fundamental scorecard
6 of 25 checks passed on LFWD’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.27 | -0.45 | -0.18 | -66.67% |
| Aug 14, 2024 | Jun 1, 2024 | -0.53 | -0.50 | +0.03 | +5.66% |
| May 15, 2024 | Mar 1, 2024 | -0.70 | -0.73 | -0.03 | -4.29% |
| Feb 27, 2024 | Dec 1, 2023 | -0.91 | -0.35 | +0.56 | +61.54% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Lifeward Ltd.
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- golifeward.com
News
HC Wainwright & Co. Maintains Buy on Lifeward, Lowers Price Target to $8
Head to Head Survey: Lifeward (NASDAQ:LFWD) vs. GN Store Nord (OTCMKTS:GNNDY)
12 Health Care Stocks Moving In Friday's Intraday Session
Lifeward (LFWD) Reports Q3 Loss, Misses Revenue Estimates Lifeward Q3 Adj. EPS $(1.32) Misses $(0.82) Estimate, Sales $5.428M Miss $7.239M Estimate
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
Lifeward's ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Your note
Sign in to keep a note on LFWD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAN ARYEH | Director | Sale | Aug 14, 2023 | 0 |
| DYKAN JEFF | Director | Stock Award(Grant) | Sep 12, 2023 | 0 |
| JASINSKI LAWRENCE J | Chief Executive Officer | Sale | Sep 12, 2024 | 0 |
| LAWLESS MICHAEL A. | Chief Financial Officer | Purchase | May 22, 2024 | 59,863 |
| LEVY HADAR | Director | Stock Award(Grant) | Sep 12, 2023 | 0 |
| LYNCH JEANNINE | Officer | Sale | Sep 2, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kent Lake PR LLC | 4.83% | 425,000 | 633.25K | Sep 29, 2024 |
| LPL Financial LLC | 1.03% | 90,360 | 134.64K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.45% | 40,006 | 59.61K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.38% | 33,812 | 50.38K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.22% | 19,007 | 28.32K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 5,880 | 8.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DFA U.S. Targeted Value Portfolio | 0.17% | 14,949 | 22.27K | Jul 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 4,234 | 6.31K | Oct 30, 2024 |
| DFA U.S. Small Cap Series | 0.02% | 1,842 | 2.74K | Jul 30, 2024 |
| DFA Investment Dimensions-DFA VA U.S. Targeted Value Portfolio | 0.01% | 863 | 1.28K | Jul 30, 2024 |
| DFA U.S. Vector Equity Portfolio | 0.00% | 206 | 306 | Jul 30, 2024 |
